Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tonix Pharmaceuticals

12.84
+1.8817.16%
Volume:13.71M
Turnover:210.45M
Market Cap:71.78M
PE:-1.65
High:18.63
Open:10.84
Low:10.80
Close:10.96
Loading ...

Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit

GlobeNewswire
·
05 Mar

Tonix Pharmaceuticals presents new data on TNX-102 SL treatment

TIPRANKS
·
04 Mar

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

GlobeNewswire
·
04 Mar

TNXP: PDUFA Date for TNX-102 SL in Fibromyalgia of August 15, 2025…

Zacks Small Cap Research
·
24 Feb

Tonix Pharmaceuticals Rises After Preliminary 2024 Results

MT Newswires Live
·
08 Feb

Tonix Pharmaceuticals Reports FY24 Preliminary Financials: $98.8M In Cash And Cash Equivalents As Of December 31, 2024, Revenue Hits ~$10.1M Vs $7.8M YoY

Benzinga
·
07 Feb

Tonix Pharmaceuticals Holding Corp - Is NOW Debt-Free After Repaying Mortgage

THOMSON REUTERS
·
07 Feb

Tonix Pharmaceuticals Holding Corp - FDA Pdufa Goal Date for Tnx-102 Sl Is August 15, 2025

THOMSON REUTERS
·
07 Feb

Press Release: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash

Dow Jones
·
07 Feb

Tonix Pharmaceuticals announces results from Phase 1 trial for TNX-1500

TIPRANKS
·
06 Feb

Tonix Pharmaceuticals Holding Corp - Tnx-1500 Generally Well-Tolerated With Favorable Safety Profile

THOMSON REUTERS
·
06 Feb

Tonix Pharmaceuticals Holding Corp - Phase 1 Results Support Phase 2 Trial for Kidney Transplant Rejection

THOMSON REUTERS
·
06 Feb

Tonix Pharmaceuticals Holding Corp - Tnx-1500 Showed Mean Half-Life of 34-38 Days Supporting Monthly Dosing

THOMSON REUTERS
·
06 Feb

Tonix Pharmaceuticals Announces Positive Topline Results From Phase 1 Trial for Tnx-1500, a Next Generation Anti-Cd40l Mab Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases

THOMSON REUTERS
·
06 Feb

Tonix Pharmaceuticals Holding Corp - Tnx-1500 Blocked Primary and Secondary Antibody Responses at 10 Mg/Kg and 30 Mg/Kg

THOMSON REUTERS
·
06 Feb

Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of Kidney Transplant Rejection and Treatment of Autoimmune Diseases

GlobeNewswire
·
06 Feb